Ramipril + Rosiglitazone
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Impaired Glucose Tolerance
Conditions
Impaired Glucose Tolerance, Cardiovascular Disease, Glucose Metabolism Disorders
Trial Timeline
Jul 1, 2001 → Oct 1, 2006
NCT ID
NCT00095654About Ramipril + Rosiglitazone
Ramipril + Rosiglitazone is a phase 3 stage product being developed by Pfizer for Impaired Glucose Tolerance. The current trial status is completed. This product is registered under clinical trial identifier NCT00095654. Target conditions include Impaired Glucose Tolerance, Cardiovascular Disease, Glucose Metabolism Disorders.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00095654 | Phase 3 | Completed |
Competing Products
19 competing products in Impaired Glucose Tolerance